ArticleMaterials today. Bio2025
Light-triggered carbon monoxide-induced activation of enhanced ferritinophagy-mediated ferroptosis for bone metastases therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Breaking the immune "cold niche" in bone metastasis: core mechanisms of the multidimensional interwoven regulatory network and precision breakthrough strategies.Molecular cancer · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases, as a common disabling and life-threatening complication in the advanced stages of various solid tumors, continue to pose substantial therapeutic challenges due to high drug toxicity and tumor resistance. To overcome the limited efficacy and safety concerns of existing treatments, we developed a novel iron-based photocatalytic nanoplatform (ENCF), guided by second near-infrared (NIR-II) imaging, for the precise treatment of bone metastases. This platform enables in situ photocatalytic release of CO and utilizes exposed iron active sites to synergistically induce ferroptosis through a cascade of oxidative stress, autophagy and iron metabolism disruption under 808 nm laser activation. Mechanistic investigations revealed that the ENCF platform significantly downregulates PCBP2, a key regulator of ferritinophagy, while activating LC3- and ATG5-mediated autophagic pathways to accelerate FTH1 degradation and Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.